Dr. Marlo Leonen, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 2,943
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MI license 4301059106 -
Specialist
MI license 4301059106
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
- Trinity Health Ann Arbor Hospital Ann Arbor, MI
- St Joe Mercy Hospital System Livonia Livonia, MI
- Trinity Health Livingston Hospital Howell, MI
- Chelsea Hospital Chelsea, MI
Medical groups
- Iha Health Services Corporation (1,168 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,943
- Services billed
- 5,326
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 2,917 | 2,133 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 835 | 823 |
| Heart muscle strain imaging | 576 | 568 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 352 | 350 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 248 | 247 |
| Established patient office or other outpatient visit, 30-39 minutes | 231 | 197 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 164 | 164 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 99 | 97 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 94 | 91 |
| Ultrasound of heart blood flow, valves and chambers | 85 | 84 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 13 payments worth $625 in total to this clinician.
| Abbott Laboratories | $261 |
|---|---|
| Impulse Dynamics (USA) Inc. | $155 |
| Bridgebio Pharma, Inc. | $75.39 |
| Pfizer Inc. | $62.32 |
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $35.71 |
| Philips North America LLC | $20.88 |
| Baxter Healthcare | $13.87 |
| Food and Beverage | $625 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $148,067 in research payments for these studies, mostly to the institutions running them.
- EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim International GmbH - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and…
AstraZeneca UK Limited - EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
Boehringer Ingelheim International GmbH - Dapagliflozin in Acute Decompensated Heart Failure
AstraZeneca Pharmaceuticals LP - EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
Boehringer Ingelheim Pharma GmbH & Co.kg
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.